↓ Skip to main content

Berberine, a natural compound, suppresses Hedgehog signaling pathway activity and cancer growth

Overview of attention for article published in BMC Cancer, August 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (78th percentile)

Mentioned by

twitter
7 tweeters
patent
1 patent

Citations

dimensions_citation
26 Dimensions

Readers on

mendeley
20 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Berberine, a natural compound, suppresses Hedgehog signaling pathway activity and cancer growth
Published in
BMC Cancer, August 2015
DOI 10.1186/s12885-015-1596-z
Pubmed ID
Authors

Juan Wang, Yuanqiu Peng, Yuan Liu, Jun Yang, Ning Ding, Wenfu Tan

Abstract

Berberine (BBR), a natural alkaloid compound, is used as a non-prescription drug in China for treating diarrhea and gastroenteritis. Many studies have revealed that BBR possesses anticancer effect. However, the molecular mechanisms underlying its anticancer action is far from being fully elucidated. This study is aimed to determine the effect of BBR on the hedgehog (Hh) activity and the growth of cancers addiction to Hh activity. The Hh activity was determined by dual luciferase assays and quantitative RT-PCR analyses. The growth inhibition of BBR on medulloblastoma which was obtained from ptch+/-;p53-/- mice was analyzed by 5-bromo-2-deoxyuridine (Brdu) assays and by allografting the medulloblastoma into nude mice. The data were statistically analyzed by one-way analysis of variance (ANOVA), and multiple comparison between the groups was performed using Dunnett's method. In this study, we found that BBR significantly inhibited the Hh pathway activity. Meanwhile, we observed that BBR failed to affect the transcriptional factors activities provoked by tumor necrosis factor-α (TNF-α) and Prostaglandin E2 (PGE2), thus suggesting its unique property against Hh pathway activity. Further studies revealed that BBR inhibited the Hh pathway activity by potentially targeting the critical component Smoothened (Smo) and most likely shared the same binding site on Smo with cyclopamine, a classical Smo inhibitor. Finally, we demonstrated that BBR obviously suppressed the Hh-dependent medulloblastoma growth in vitro and in vivo. Collectively, our study uncovered a novel molecular mechanism responsible for the anticancer action of BBR, thus opening the way for the usage of BBR for therapeutics of cancers addiction to aberrant Hh pathway activity.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Malaysia 1 5%
Unknown 19 95%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 25%
Student > Bachelor 4 20%
Researcher 3 15%
Student > Doctoral Student 2 10%
Student > Ph. D. Student 2 10%
Other 3 15%
Unknown 1 5%
Readers by discipline Count As %
Medicine and Dentistry 7 35%
Agricultural and Biological Sciences 3 15%
Pharmacology, Toxicology and Pharmaceutical Science 2 10%
Biochemistry, Genetics and Molecular Biology 1 5%
Psychology 1 5%
Other 3 15%
Unknown 3 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 February 2022.
All research outputs
#4,235,089
of 21,769,404 outputs
Outputs from BMC Cancer
#1,049
of 7,898 outputs
Outputs of similar age
#54,376
of 253,821 outputs
Outputs of similar age from BMC Cancer
#1
of 1 outputs
Altmetric has tracked 21,769,404 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,898 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 253,821 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them